The object of the present invention is to provide novel compounds having a potent FXa inhibitory activity, shows the antithrombotic effect excellent oral administration. The general formula (1) Wherein, each independently, R 2 and R 1 represents a hydrogen atom, a hydroxyl group, an alkyl group or an alkoxy group Q 1 is a tricyclic or bicyclic saturated or unsaturated which may have a substituent or a condensed hydrocarbon group, a tricyclic or bicyclic saturated or unsaturated which may have a substituent shows a fused heterocyclic group Q 2 represents an alkylene group having 1 to 6 carbon atoms branched single bond, or a linear, an alkenylene group having 2 to 6 carbon atoms branched or straight chainR 3 and R 4 represents an alkyl group or the like m and n indicates the number of 0 to 3 Q 4 represents an aryl group Medicine containing the same, and the compound represented and T 1 T 0 is a) shows the carbonyl group, and the like.本発明の目的は、強力なFXa阻害作用を有し、経口投与で優れた抗血栓効果を示す新規な化合物を提供すること。一般式(1)[式中、R1およびR2は各々独立して、水素原子、水酸基、アルキル基またはアルコキシ基を示し;Q1は、置換基を有することもある飽和もしくは不飽和の2環性または3環性の縮合炭化水素基、または置換基を有することもある飽和もしくは不飽和の2環性または3環性の縮合複素環式基等を示し;Q2は、単結合、直鎖状もしくは分枝状の炭素数1~6のアルキレン基、直鎖状もしくは分枝状の炭素数2~6のアルケニレン基等を示し;R3及びR4はアルキル基等を示し;mおよびnは0~3の数を示し;Q4はアリール基を示し;T0及びT1はカルボニル基等を示す)で表される化合物及びこれを含有する医薬。
